| Nothing but NET: a review of neuroendocrine tumors and carcinomas B Oronsky, PC Ma, D Morgensztern, CA Carter Neoplasia 19 (12), 991-1002, 2017 | 685 | 2017 |
| ctDNA guiding adjuvant immunotherapy in urothelial carcinoma T Powles, ZJ Assaf, N Davarpanah, R Banchereau, BE Szabados, ... Nature 595 (7867), 432-437, 2021 | 392 | 2021 |
| Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial A Thomas, A Rajan, A Berman, Y Tomita, C Brzezniak, MJ Lee, S Lee, ... The Lancet Oncology 16 (2), 177-186, 2015 | 296 | 2015 |
| Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial A Lopez-Chavez, A Thomas, A Rajan, M Raffeld, B Morrow, R Kelly, ... Journal of clinical oncology 33 (9), 1000-1007, 2015 | 254 | 2015 |
| A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, ... Clinical cancer research 18 (8), 2344-2351, 2012 | 190 | 2012 |
| What's new in SCLC? A review B Oronsky, TR Reid, A Oronsky, CA Carter Neoplasia 19 (10), 842-847, 2017 | 175 | 2017 |
| A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer B Oronsky, CM Ray, AI Spira, JB Trepel, CA Carter, HM Cottrill Medical oncology 34, 1-7, 2017 | 175 | 2017 |
| A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer RJ Kelly, A Thomas, A Rajan, G Chun, A Lopez-Chavez, E Szabo, ... Annals of oncology 24 (10), 2601-2606, 2013 | 168 | 2013 |
| Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction CW Ogden, P Reddy, H Johnson, JWA Ramsay, C Carter The Lancet 341 (8836), 14-17, 1993 | 165 | 1993 |
| TGF-beta: a master immune regulator C Larson, B Oronsky, CA Carter, A Oronsky, SJ Knox, D Sher, TR Reid Expert opinion on therapeutic targets 24 (5), 427-438, 2020 | 140 | 2020 |
| Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial A Rajan, CA Carter, A Berman, L Cao, RJ Kelly, A Thomas, S Khozin, ... The lancet oncology 15 (2), 191-200, 2014 | 132 | 2014 |
| Activation of Prostate-Specific Antigen Precursor (pro-PSA) by Prostin, a Novel Human Prostatic Serine Protease Identified by Degenerate PCR, TK Takayama, CA Carter, T Deng Biochemistry 40 (6), 1679-1687, 2001 | 109 | 2001 |
| APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors N Roper, S Gao, TK Maity, AR Banday, X Zhang, A Venugopalan, ... Cell reports 26 (10), 2651-2666. e6, 2019 | 105 | 2019 |
| A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study A Thomas, A Rajan, E Szabo, Y Tomita, CA Carter, B Scepura, ... Clinical Cancer Research 20 (21), 5392-5402, 2014 | 105 | 2014 |
| Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era CA Carter, T Donahue, L Sun, H Wu, DG McLeod, C Amling, R Lance, ... Journal of clinical oncology 21 (21), 4001-4008, 2003 | 103 | 2003 |
| Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study T Reid, B Oronsky, J Scicinski, CL Scribner, SJ Knox, S Ning, DM Peehl, ... The Lancet Oncology 16 (9), 1133-1142, 2015 | 100 | 2015 |
| A review of clinical radioprotection and chemoprotection for oral mucositis B Oronsky, S Goyal, MM Kim, P Cabrales, M Lybeck, S Caroen, ... Translational oncology 11 (3), 771-778, 2018 | 96 | 2018 |
| Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer CA Carter, A Rajan, C Keen, E Szabo, S Khozin, A Thomas, C Brzezniak, ... Annals of Oncology 27 (4), 693-699, 2016 | 93 | 2016 |
| Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management B Oronsky, S Caroen, A Oronsky, VE Dobalian, N Oronsky, M Lybeck, ... Cancer chemotherapy and pharmacology 80, 895-907, 2017 | 92 | 2017 |
| Just eat it: A review of CD47 and SIRP-α antagonism B Oronsky, C Carter, T Reid, F Brinkhaus, SJ Knox Seminars in Oncology 47 (2-3), 117-124, 2020 | 66 | 2020 |
